Blood plasma is the liquid component of blood constituting the extracellular matrix. Blood plasma plays a crucial role in maintaining the electrolyte and osmotic balance whilst preventing infection and blood disorders in the body. It primarily consists of water along with other components such as immunoglobulin, dissolved proteins, glucose, clotting factors, electrolytes and hormones. Plasma derivatives are the concentrates of specific proteins which require pooling of plasma from large number of donors. For instance, it requires more than hundred plasma donations to produce sufficient immunoglobulin for treating an immune deficient patient for one year. This has resulted in lucrative opportunities for technological innovations to improve the productivity of plasma derived products. Rising demand for plasma derived products owing to a huge patient pool and unavailability of alternative treatments, would drive the market to the next level. For instance, in case of haemophilia, currently there is no definite cure, and the patient may require a lifelong infusion of plasma derived products. The major factors contributing in the market growth are, rising disease awareness and education, organized network of donor centres and increasing commitment to research. However, high cost of treatment and safety concerns associated with blood transfusion, are likely to restrict the growth of market.
The global blood plasma derivatives market is segmented on the basis of type, application and geography. On the basis of type, the market is segmented into, Fresh Frozen Plasma (FFP), Intravenous immunoglobulin (IVIG), Albumin, Factor VIII, Factor IX and Other components. The market, on the basis of application is segmented into Hemophilia A, Hemophilia B, Von Willebrand Disease and Other Factor Deficiencies. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific, and LAMEA.
Few strategies adopted by industry players are acquisition and geographical expansion. For instance, Grigols, market leader in plasma products, has acquired numerous companies in the past few years such as Progenika biopharma, Araclon Biotech, and Talecris Biotherapeutics. In Jan 2014, Grigols acquired the blood transfusion diagnostics unit of Novartis AG to reinforce its business. The company has also expanded its geographic presence in regions such as India, Japan, Switzerland and China. The companies profiled in the report include, Grifols, S.A., Baxter International Inc., CSL Limited, Octapharma AG, Kedrion S.p.A, LFB S.A., Bain Capital, LLC and Biotest AG.
KEY MARKET BENEFITS
- Comprehensive analysis of factors that drive and restrict the growth of the global blood plasma derivatives market is provided
- The market estimations are made in the report by conducting high-end analysis of the key market segments for the period of 2014‐2020, which would enable the stakeholders to capitalize on prevailing market opportunities
- An in depth analysis of key segments of the market demonstrates the types of blood plasma derivatives along with the applications in the blood plasma derivative market
- SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
- Region-wise blood plasma derivatives market conditions are comprehensively analysed in the report
- Competitive intelligence highlights the business practises followed by leading market players across the geographies
Blood Plasma Derivatives Market Is Segmented Below:
Blood Plasma Derivatives Market ‐ By Type
- Fresh Frozen Plasma (FFP)
- Intravenous immunoglobulin (IVIG)
- Factor VIII
- Factor IX
- Other components
Blood Plasma Derivatives Market ‐ By Application
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Other Factor Deficiencies
Blood Plasma Derivatives Market ‐ By Geography
- North America